Abstract. Intestinal commensals are being increasingly appreciated for their role in modulating the therapeutic efficacy of cancer therapies. Human-associated bacterial strains with demonstrable ...

Abstract. NL-201 is a computationally-designed IL-2/IL-15 cytokine mimetic under investigation in a phase 1 clinical trial for patients with solid tumors. This de novo protein signals through the ...

Abstract 4127: ANV600 is a potent, C is -signaling, non-alpha IL-2 agonist which efficiently expands intratumoral stem-like CD8 T cells ...

Abstract. KRAS is the most frequently mutated oncogene in cancer and encodes a key signaling protein in tumors. The p.G12C mutation of KRAS is present in approximately 13% of lung adenocarcinoma, 3% ...

Abstract. Glyphosate is the most commercially successful and the most widely used herbicide in the United States and worldwide. It represents about 50% of United States herbicide usage at ...

Abstract. Pancreatic cancer is an aggressive cancer characterized by high mortality and poor prognosis with survival of less than 5 years when advanced. Several studies showed that the ivermectin has ...

This review provides a comprehensive analysis of the current therapies targeting the TME, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic ...

Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...

Abstract. MEDI7247 is a first in class ADC consisting of a human anti-ASCT2 monoclonal antibody site specifically conjugated to DNA cross-linking pyrrolobenzodiazepine (PBD) dimers. ASCT2 (SLC1A5) is ...

The incidence of thyroid cancer has risen dramatically in the United States over the past four decades, with similar patterns observed internationally. Thyroid cancer currently ranks as the 13th most ...

Summary:. To date, immune targeting agents have provided limited benefits in patients with metastatic prostate cancer. Bispecific T-cell engagers, especially targeting STEAP1, have shown encouraging ...

Abstract. Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have been approved for treatment of metastatic ER+ HER2− breast cancer as monotherapy or in combination with endocrine therapy. However, ...